# A multi-omics study on monozygotic twins discordant for amyotrophic lateral sclerosis and literature review underline a potential role for innate immunity and epigenetic dysregulation in disease mechanisms

**Authors:** Martina Tosi, Francesco Favero, Miriam Zuccalà, Endri Visha, Fjorilda Caushi, Nadia Barizzone, Nicola Pomella, Laura Follia, Lucia Corrado, Davide Corà, Loredana Martignetti, Maurizio Leone, Sandra D’Alfonso

PMC · DOI: 10.1007/s10072-026-08813-y · 2026-02-05

## TL;DR

This study explores how differences in immune system and epigenetic factors may explain why identical twins have different risks for ALS.

## Contribution

The study uses multi-omics data from identical twins with differing ALS status to highlight innate immunity and epigenetic dysregulation in ALS.

## Key findings

- Transcriptomic and epigenetic differences were found between ALS-discordant identical twins.
- Immune system functions and brain development pathways were implicated in ALS mechanisms.
- NK cell activation and chemokine production pathways were highlighted as potentially shared mechanisms in ALS.

## Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by motor neuron degeneration. Although genetic contributions to both familial and sporadic ALS (sALS) cases are well established, a substantial portion of ALS heritability remains unexplained, suggesting the involvement of other genetic and epigenetic factors.

To address this gap, we have devised a comprehensive multi-omics approach in a pair of Italian monozygotic twins discordant for ALS, performing DNA methylation, transcriptomic, and whole exome sequencing (WES). We then conducted a structured literature research on ALS-discordant monozygotic twins (n = 45) and on case-control sALS (~ 7000 patients and ~ 3000 controls), investigated for at least one of the omics approaches.

Our exploratory analysis reveals distinct transcriptomic and epigenetic profiles underlying the discordant disease phenotypes in genetically identical individuals, particularly implicating immune system functions and brain development pathways. Notably, a comprehensive comparison of our results with existing literature underlined the involvement of pathways related to NK cell activation, chemokine production, and signal transduction, suggesting potential shared disease associated mechanisms across ALS cases.

This hypothesis-generating study, although limited by the sample size, demonstrates the utility of multi-omics approaches in uncovering broader pathological insights into ALS, speculating on the possible contribution of innate immunity and epigenetic dysregulation in disease processes. This work provides a foundation for future research aimed at identifying disease-associated processes and biomarkers.

The online version contains supplementary material available at 10.1007/s10072-026-08813-y.

## Linked entities

- **Diseases:** Amyotrophic lateral sclerosis (MONDO:0004976), ALS (MONDO:0004976)

## Full-text entities

- **Genes:** CACNA1G (calcium voltage-gated channel subunit alpha1 G) [NCBI Gene 8913] {aka Ca(V)T.1, Cav3.1, NBR13, SCA42, SCA42ND}, KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 22914] {aka CD314, D12S2489E, KLR, NKG2-D, NKG2D}, PKIB (cAMP-dependent protein kinase inhibitor beta) [NCBI Gene 5570] {aka PRKACN2}, B3GAT1 (beta-1,3-glucuronyltransferase 1) [NCBI Gene 27087] {aka CD57, GLCATP, GLCUATP, HNK1, LEU7, NK-1}, C1QB (complement C1q B chain) [NCBI Gene 713] {aka C1QD2}, KLRC4 (killer cell lectin like receptor C4) [NCBI Gene 8302] {aka NKG2-F, NKG2F}, C1QC (complement C1q C chain) [NCBI Gene 714] {aka C1Q-C, C1QD3, C1QG}, HPRT1 (hypoxanthine phosphoribosyltransferase 1) [NCBI Gene 3251] {aka HGPRT, HPRT}, KLRC3 (killer cell lectin like receptor C3) [NCBI Gene 3823] {aka NKG2-E, NKG2E}, RAP1A (RAP1A, member of RAS oncogene family) [NCBI Gene 5906] {aka C21KG, G-22K, KREV-1, KREV1, RAP1, SMGP21}, PF4V1 (platelet factor 4 variant 1) [NCBI Gene 5197] {aka CXCL4L1, CXCL4V1, PF4-ALT, PF4A, SCYB4V1}, ZHX2 (zinc fingers and homeoboxes 2) [NCBI Gene 22882] {aka AFR1, RAF}, SLAMF8 (SLAM family member 8) [NCBI Gene 56833] {aka BLAME, CD353, SBBI42}, CD160 (CD160 molecule) [NCBI Gene 11126] {aka BY55, NK1, NK28}, GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351] {aka ACT2, AT744.1, G-26, HC21, LAG-1, LAG1}, LYPD2 (LY6/PLAUR domain containing 2) [NCBI Gene 137797] {aka LYPDC2, UNQ430}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, PDGFRB (platelet derived growth factor receptor beta) [NCBI Gene 5159] {aka CD140B, IBGC4, IMF1, JTK12, KOGS, OPDKD}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, EPHB2 (EPH receptor B2) [NCBI Gene 2048] {aka BDPLT22, CAPB, DRT, EK5, EPHT3, ERK}, GOLGA2P5 (GOLGA2 pseudogene 5) [NCBI Gene 55592] {aka GOLGA2B, GOLGA2L1}, IL34 (interleukin 34) [NCBI Gene 146433] {aka C16orf77, IL-34}, SERPING1 (serpin family G member 1) [NCBI Gene 710] {aka C1IN, C1INH, C1NH, HAE1, HAE2}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, NKG7 (natural killer cell granule protein 7) [NCBI Gene 4818] {aka GIG1, GMP-17, p15-TIA-1}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, VAX1 (ventral anterior homeobox 1) [NCBI Gene 11023] {aka MCOPS11}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, CSF1 (colony stimulating factor 1) [NCBI Gene 1435] {aka CSF-1, MCSF, PG-M-CSF}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, CXCL9 (C-X-C motif chemokine ligand 9) [NCBI Gene 4283] {aka CMK, Humig, MIG, SCYB9, crg-10}
- **Diseases:** cytotoxicity (MESH:D064420), muscle atrophy (MESH:D009133), neurotoxic (MESH:D020258), motor neuron disease (MESH:D016472), cancer (MESH:D009369), degeneration (MESH:D009410), neuroinflammatory (MESH:D000090862), neurodegeneration (MESH:D019636), inflammatory (MESH:D007249), ALS (MESH:D000690), natural (MESH:D012893), fALS (MESH:C531617), weakness (MESH:D018908)
- **Chemicals:** Ca2+ (-), glucose (MESH:D005947), calcium (MESH:D002118), cholesterol (MESH:D002784), steroid (MESH:D013256)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12872720/full.md

---
Source: https://tomesphere.com/paper/PMC12872720